Logo

CJMB

CALLAN JMB INC.

CJMB

CALLAN JMB INC. • NASDAQ
$2.49 ▲ 2.05% (+0.05)
Market Cap $11.16 M
52w High $7.76
52w Low $2.08
Dividend Yield 0%
P/E -1.6
Volume 29.09K
Outstanding Shares 4.48M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $1.447M ▼ $2.372M ▲ $-2.731M ▼ -188.77% ▼ $-0.61 ▼ $-2.688M ▼
Q2-2025 $1.666M ▲ $2.047M ▲ $-1.398M ▼ -83.869% ▲ $-0.31 ▲ $-1.362M ▼
Q1-2025 $1.449M ▲ $1.854M ▲ $-1.241M ▲ -85.595% ▲ $-0.32 ▲ $-1.198M ▲
Q4-2024 $1.352M ▼ $1.692M ▲ $-1.295M ▼ -95.806% ▼ $-0.43 ▼ $-1.234M ▼
Q3-2024 $1.435M $1.245M $-804.987K -56.082% $-0.27 $-745.352K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $2.79M ▼ $7.736M ▼ $3.561M ▲ $4.176M ▼
Q2-2025 $4.224M ▼ $8.966M ▲ $3.14M ▲ $5.825M ▼
Q1-2025 $5.22M ▲ $8.456M ▲ $1.648M ▼ $6.808M ▲
Q4-2024 $2.098M ▼ $5.083M ▼ $1.909M ▼ $3.173M ▼
Q3-2024 $2.809M $6.381M $1.967M $4.414M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.731M ▼ $-1.763M ▼ $-169.39K ▲ $497.75K ▲ $-1.434M ▼ $-1.932M ▼
Q2-2025 $-1.401M ▼ $-563.272K ▲ $-432.506K ▼ $0 ▼ $-995.778K ▼ $-995.778K ▲
Q1-2025 $-1.241M ▲ $-1.562M ▼ $-15K ▼ $4.699M ▲ $3.122M ▲ $-1.577M ▼
Q4-2024 $-1.295M ▼ $-723.173K ▼ $0 ▲ $11.815K ▲ $-711.358K ▼ $-723.173K ▼
Q3-2024 $-804.987K $988K $-293 $-26.127K $961.582K $987.709K

Five-Year Company Overview

Income Statement

Income Statement CJMB’s income statement reflects a very small, early-stage business with modest revenue and uneven profitability. Revenue has been tiny and not yet showing strong, consistent growth. The company moved from being profitable a couple of years ago to roughly breakeven or slightly loss-making most recently. That suggests rising costs or one‑off items weighing on results while the top line has not yet scaled enough to absorb operating expenses. Overall, this looks like a niche operator still in the build‑out phase, where financial performance can swing from year to year and is not yet stabilized.

Balance Sheet

Balance Sheet The balance sheet appears very light, with a small asset base and no meaningful debt, which reduces financial leverage risk but also signals limited scale and resources. Cash balances have come down from prior levels, and equity has edged lower, which is consistent with recent slim or negative earnings and likely ongoing investment in the business. In plain terms, CJMB looks lean and relatively unburdened by lenders, but it does not yet have the financial depth of a larger logistics player, leaving less cushion if growth takes longer than expected.

Cash Flow

Cash Flow Historically, CJMB has generated modest positive cash from operations and free cash flow, but the latest year looks closer to breakeven. Capital spending has been minimal, indicating that most investment is through operating expenses rather than heavy physical assets. This low‑capex, asset‑light profile fits a tech‑enabled logistics model but also means the company’s ability to fund growth depends heavily on maintaining positive operating cash flow or raising outside capital. The recent flattening of cash generation suggests a period of consolidation or reinvestment rather than cash-rich expansion.

Competitive Edge

Competitive Edge CJMB occupies a narrow but important niche: temperature‑controlled logistics and emergency preparedness for life sciences and public health. Its strengths lie in specialized know‑how, long experience in emergency stockpile management, and deep relationships with government and healthcare clients. The service‑disabled veteran‑owned status adds an edge in winning public contracts. The integrated tech stack—real‑time shipment monitoring, regulated inventory management, and temperature‑tracking devices—creates switching costs and a clear differentiation from generic freight providers. However, its small size, concentration in a few key customers and programs, and exposure to government budget decisions are notable structural risks.

Innovation and R&D

Innovation and R&D Innovation is a clear focal point for CJMB. The company has built a proprietary ecosystem around its Sentry monitoring platform, compliant inventory system, and data loggers, all tailored to highly regulated, temperature‑sensitive products. The SHIP2Q process and the “rent‑a‑shipper” model are distinctive, blending cost savings, sustainability, and quality assurance. CJMB is also experimenting beyond core logistics: expanding into food sampling logistics, exploring oral drug delivery manufacturing partnerships, and building a presence in India for global pharma supply chains. These moves show ambition to turn its logistics expertise into a broader, tech‑enabled supply‑chain services platform, though they add execution complexity for a small firm.

Summary

Overall, CJMB looks like a specialized, early‑stage logistics and technology company with more strategic promise than mature financial strength at this point. The financials show a tiny, somewhat volatile business still working toward steady profitability and scale, with a slim balance sheet but little debt. Its real story is in its niche: critical cold‑chain and emergency preparedness services, backed by proprietary technology and advantaged access to government and healthcare customers. Future performance will likely hinge on how well the company can convert its strong positioning and innovation pipeline into consistent revenue growth, diversify beyond a few large contracts, and sustain positive cash flow while it expands into new markets and geographies.

NEWS

November 14, 2025 · 4:05 PM UTC

Callan JMB Announces Third Quarter 2025 Financial Results and Provides Business Update

Read more

November 10, 2025 · 8:45 AM UTC

Callan JMB Expands Logistics Platform Into Food Sampling Sector, Advancing Multi-Variant Growth Strategy

Read more

October 13, 2025 · 9:00 AM UTC

Callan JMB Upgrades Sentry Monitoring System Technology with Sentry 4 for Mobile Temperature Monitoring

Read more

October 10, 2025 · 1:00 PM UTC

Callan JMB Announces Participation in the LD Micro Main Event XIX Conference on October 19-21, 2025

Read more

September 2, 2025 · 9:00 AM UTC

Callan JMB to Participate in Upcoming September Conferences

Read more